

23 August 2024

Asthma Treatments

Please note: Difficult asthma data is from April to June 2024. We do not hold data for July due to switching to encompass and are currently streamlining our reports.

Q1. How many patients have been treated (for any condition) in the last 4 months with:

- **Benralizumab** 135
- **Dupilumab** 64
- **Omalizumab** 22
- **Reslizumab** 0
- **Mepolizumab** 227
- **Tezepelumab** 16

Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:

- **Age 6-11** Difficult asthma do not treat under-18s
- **Age 12-17** Difficult asthma do not treat under-18s
- **Age 18 and above** 464

Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:

- **Dupilumab** 64
- **Omalizumab** 22